PBYI Puma Biotechnology Inc

11.22
-0.44  -4%
Previous Close 11.66
Open 11.76
Price To Book 9.93
Market Cap 433,231,655
Shares 38,612,447
Volume 870,747
Short Ratio
Av. Daily Volume 1,354,777

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released at ASCO June 3, 2017.
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 additional data presented July 3, 2019 at ESMO. Median PFS 1.8 months. 2/20 partial responses. 4/20 stable disease.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 data at ASCO June 2, 2019. Discontinuation 14-45%.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
NDA filing announced July 1, 2019.
Neratinib - NALA
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Approval announced July 17, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
Neratinib (NERLYNX)
Extended adjuvant HER2-positive early stage breast cancer
Phase 1/2 interim data presented at ASCO June 2018. 9 PRs, 3CRs out of 20 patients.
Neratinib plus Kadcyla (T-DM1)
HER2-positive metastatic breast cancer

Latest News

  1. Implied Volatility Surging for Puma Biotech (PBYI) Stock Options
  2. Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
  3. Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
  4. Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
  5. Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake
  6. One Thing To Remember About The Puma Biotechnology, Inc. (NASDAQ:PBYI) Share Price
  7. Does Market Volatility Impact Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Share Price?
  8. See what the IHS Markit Score report has to say about Puma Biotechnology Inc.
  9. Did You Manage To Avoid Puma Biotechnology's (NASDAQ:PBYI) Devastating 77% Share Price Drop?
  10. Edited Transcript of PBYI earnings conference call or presentation 9-May-19 8:30pm GMT
  11. Puma Biotech (PBYI) Down 53.9% Since Last Earnings Report: Can It Rebound?
  12. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  13. Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
  14. CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
  15. Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
  16. Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference